COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
195M of 174M shares
Institutional holders
323
66 new, 44 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 8 sales
Net sold $383.89M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 9,053,118 | 6.49% | 13G (passive) | Jul 7, 2025 |
| Paradigm BioCapital Advisors LP | 8,963,655 | 7.90% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 8,691,589 | 5.08% | 13G (passive) | Jun 30, 2026 |
| Kynam Capital Management, LP | 7,886,172 | 5.54% | 13G (passive) amendment | Sep 30, 2025 |
| Bong Y Koh | 6,446,917 | 5.80% | 13G (passive) amendment | Sep 30, 2024 |
| Michael Kramarz | 6,408,060 | 5.50% | 13G (passive) | Jul 7, 2025 |
| Abigail P. Johnson | 16,569,256 | 15.00% | 13G (passive) amendment | Dec 31, 2024 |
| Fairmount Healthcare Fund II GP LLC | 15,356,918 | 8.60% | 13D (active) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 13,593,063 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors GP LLC | 10,352,449 | 9.10% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COGT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 25,681,174 | 14.80% | $993.86M | +2,558,426 | 0.04% |
| BlackRock, Inc. | 17,352,646 | 10.00% | $671.55M | +1,307,632 | 0.01% |
| Vanguard Portfolio Management LLC | 8,072,411 | 4.65% | $312.40M | +739,078 | 0.01% |
| Vanguard Capital Management LLC | 7,412,330 | 4.27% | $286.86M | +517,371 | 0.01% |
| State Street Corp | 6,964,919 | 4.01% | $269.54M | +1,301,376 | 0.01% |
| Jupiter Topco LLC | 6,624,848 | 3.82% | $256.42M | New | 0.10% |
| Fairmount Funds Management LLC | 5,503,418 | 3.17% | $212.98M | – | 14.08% |
| Deerfield Management Company, L.P. (Series C) | 5,006,104 | 2.88% | $193.74M | −4,037,799 | 2.02% |
| TCG Crossover Management, LLC | 4,854,436 | 2.80% | $187.87M | −92,458 | 4.52% |
| Price T Rowe Associates Inc /Md/ | 4,652,727 | 2.68% | $180.06K | +1,439,912 | 0.02% |
| Geode Capital Management, LLC | 4,508,998 | 2.60% | $174.53M | +809,479 | 0.01% |
| Wellington Management Group Llp | 4,343,977 | 2.50% | $168.11M | +765,355 | 0.03% |
| Kynam Capital Management, LP | 3,667,097 | 2.11% | $141.92M | −370,234 | 7.84% |
| Lord, Abbett & Co. LLC | 3,431,030 | 1.98% | $132.78K | +249,760 | 0.38% |
| Polar Capital Holdings Plc | 3,232,905 | 1.86% | $125.11M | New | 0.30% |
| Commodore Capital LP | 3,050,000 | 1.76% | $118.04M | +161,993 | 7.03% |
| Assenagon Asset Management S.A. | 2,883,512 | 1.66% | $111.59M | +2,587,862 | 0.07% |
| Invesco Ltd. | 2,609,141 | 1.50% | $100.97M | +179,512 | 0.01% |
| Woodline Partners LP | 2,603,162 | 1.50% | $100.74M | +1,093,605 | 0.31% |
| Pictet Asset Management Holding SA | 2,393,515 | 1.38% | $92.63M | +594,747 | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 323 | 195M | 100.0% | 66 / 137 | 86 / 44 | 40M | 26M |
| Q1 2026 | 305 | 187M | 100.0% | 80 / 116 | 82 / 36 | 45M | 21M |
| Q4 2025 | 267 | 174M | 100.0% | 95 / 93 | 64 / 21 | 44M | 28M |
| Q3 2025 | 195 | 159M | 91.8% | 41 / 87 | 46 / 24 | 50M | 26M |
| Q2 2025 | 180 | 136M | 78.2% | 30 / 78 | 37 / 35 | 20M | 18M |
| Q1 2025 | 186 | 134M | 76.9% | 32 / 67 | 50 / 20 | 21M | 9M |
| Q4 2024 | 176 | 122M | 70.1% | 38 / 63 | 46 / 23 | 19M | 19M |
| Q3 2024 | 161 | 122M | 70.2% | 32 / 53 | 48 / 19 | 17M | 10M |
| Q2 2024 | 149 | 122M | 70.5% | 28 / 55 | 48 / 22 | 28M | 19M |
| Q1 2024 | 146 | 113M | 65.1% | 33 / 63 | 37 / 30 | 32M | 12M |
| Q4 2023 | 144 | 94M | 54.1% | 36 / 61 | 30 / 24 | 23M | 20M |
| Q3 2023 | 135 | 91M | 52.4% | 12 / 58 | 36 / 13 | 11M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of COGT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,156,952 | 2.97% | $199.57M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,279,868 | 2.47% | $165.63M | 0.20% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,724,033 | 2.15% | $144.12M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,172,989 | 1.83% | $122.79M | 1.14% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 2,509,157 | 1.45% | $97.68M | 1.11% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 2,358,212 | 1.36% | $91.26M | 0.13% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,959,435 | 1.13% | $75.83M | 0.08% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 1,873,600 | 1.08% | $72.94M | 0.17% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,834,818 | 1.06% | $71.43M | 3.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,822,133 | 1.05% | $70.94M | 0.21% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,750,000 | 1.01% | $61.18M | 1.06% | May 31, 2026 |
| Lord Abbett Growth Leaders Fund | 1,730,027 | 1.00% | $67.35M | 0.91% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,604,794 | 0.92% | $56.10M | 1.07% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,539,224 | 0.89% | $59.57M | 0.39% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 1,406,858 | 0.81% | $49.18M | 0.83% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew R. Robbins | President and CEO, Director | 657,503 | 0.38% | May 21, 2026 |
| Evan Kearns | Chief Legal Officer | 109,398 | 0.06% | Dec 30, 2025 |
| John Edward Robinson | Chief Scientific Officer | 140,002 | 0.08% | Dec 30, 2025 |
| Jessica Sachs | Chief Medical Officer | 133,938 | 0.08% | Dec 30, 2025 |
| John L. Green | Chief Financial Officer | 131,834 | 0.08% | Dec 30, 2025 |
| Cole Pinnow | Chief Commercial Officer | 97,450 | 0.06% | Dec 19, 2025 |
| Arlene Morris | Director | 45,510 | 0.03% | Aug 31, 2026 |
| Karen Jean Ferrante | Director | – | – | Jul 6, 2026 |
| Matthew Ros | Director | – | – | Jun 11, 2026 |
| Todd Shegog | Director | – | – | Jun 11, 2026 |
| Peter Evan Harwin | Director | – | – | Jun 11, 2026 |
| Christopher W. Cain | Director | – | – | Jun 11, 2026 |
| Funds Management LLC Fairmount | Director | 5,503,418 | 3.17% | Mar 31, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Arlene Morris Director | Aug 27, 2026 | Option exercise | +3,583 | $2.52 | $9.03K | 45,510 |
| Arlene Morris Director | Aug 27, 2026 | Sale(10b5-1 plan) | −42,349 | $37.09 | $1.57M | 3,161 |
| Arlene Morris Director | Aug 27, 2026 | Sale(10b5-1 plan) | −3,161 | $37.54 | $118.66K | 0 |
| Arlene Morris Director | Aug 27, 2026 | Option exercise | +41,927 | $5.64 | $236.47K | 41,927 |
| Andrew R. Robbins President and CEO, Director | May 19, 2026 | Gift | −160,000 | – | – | 497,503 |
| Andrew R. Robbins President and CEO, Director | May 19, 2026 | Gift | +160,000 | – | – | 160,000 |
| Funds Management LLC Fairmount Director | Mar 31, 2026 | Sale | −7,000,000 | $34.66 | $242.62M | 5,503,418 |
| Funds Management LLC Fairmount Director | Mar 31, 2026 | Conversion | +7,000,000 | – | – | 12,503,418 |
| Funds Management LLC Fairmount Director | Jan 22, 2026 | Sale | −3,500,000 | $36.40 | $127.40M | 5,503,418 |
| John L. Green Chief Financial Officer | Dec 26, 2025 | Sale | −77,000 | $38.68 | $2.98M | 131,834 |
| Jessica Sachs Chief Medical Officer | Dec 26, 2025 | Sale | −82,642 | $38.70 | $3.20M | 133,938 |
| John Edward Robinson Chief Scientific Officer | Dec 26, 2025 | Sale | −90,000 | $38.74 | $3.49M | 140,002 |
| Evan Kearns Chief Legal Officer | Dec 26, 2025 | Sale | −65,000 | $38.70 | $2.52M | 109,398 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Award | +840,000 | – | – | 1,025,000 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Award | +185,000 | – | – | 185,000 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Tax withholding | −367,497 | $39.45 | $14.50M | 657,503 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Award | +300,000 | – | – | 353,841 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Award | +50,000 | – | – | 53,841 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Tax withholding | −145,007 | $39.45 | $5.72M | 208,834 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Award | +50,000 | – | – | 97,450 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Tax withholding | −94,800 | $39.45 | $3.74M | 216,650 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Award | +214,000 | – | – | 311,450 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Tax withholding | −125,602 | $39.45 | $4.95M | 174,398 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Award | +260,000 | – | – | 300,000 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Award | +40,000 | – | – | 40,000 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Award | +50,000 | – | – | 51,296 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Award | +320,000 | – | – | 371,296 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Tax withholding | −154,716 | $39.45 | $6.10M | 216,580 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Award | +320,000 | – | – | 370,000 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Tax withholding | −139,998 | $39.45 | $5.52M | 230,002 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Award | +50,000 | – | – | 50,000 |
| Funds Management LLC Fairmount Director | Jul 10, 2025 | Buy | +2,777,777 | $9.00 | $25.00M | 9,003,418 |
| Cole Pinnow Chief Commercial Officer | Jan 14, 2025 | Buy | +43,750 | $7.60 | $332.50K | 45,848 |
| Funds Management LLC Fairmount Director | Jun 10, 2024 | Option exercise | +1,500,000 | – | – | 6,225,641 |
| Funds Management LLC Fairmount Director | Mar 28, 2024 | Other | −286,851 | – | – | 0 |
| Funds Management LLC Fairmount Director | Mar 28, 2024 | Other | +286,851 | – | – | 4,725,641 |
| Funds Management LLC Fairmount 10% owner | Feb 16, 2024 | Award | +1,166,666 | $7.50 | $8.75M | 4,438,790 |
| Funds Management LLC Fairmount 10% owner | Jun 9, 2023 | Buy | +800,000 | $12.00 | $9.60M | 3,272,124 |
| Jessica Sachs Chief Medical Officer | Jun 30, 2022 | Award | +622 | $7.40 | $4.60K | 622 |
| Funds Management LLC Fairmount 10% owner | Jun 16, 2022 | Buy | +1,200,000 | $8.25 | $9.90M | 2,472,124 |
| Jessica Sachs Chief Medical Officer | Dec 31, 2021 | Award | +674 | $6.82 | $4.60K | 674 |
| John L. Green Chief Financial Officer | Apr 26, 2021 | Sale | −17,813 | $8.86 | $157.82K | 3,841 |
| John L. Green Chief Financial Officer | Feb 25, 2021 | Award | +524 | – | – | 21,654 |
| John L. Green Chief Financial Officer | Dec 1, 2020 | Award | +1,748 | – | – | 1,748 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 18, 2020 | Buy | +101,000 | $2.62 | $264.62K | 4,355,273 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 17, 2020 | Buy | +250,000 | $2.57 | $642.50K | 4,254,273 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 14, 2020 | Buy | +100,000 | $2.30 | $230.00K | 4,004,273 |
| Funds Management LLC Fairmount 10% owner | Jul 6, 2020 | Other | +1,147,406 | – | – | 1,147,406 |
| Funds Management LLC Fairmount 10% owner | Jul 6, 2020 | Other | +5,088,497 | – | – | 5,088,497 |
| John L. Green Chief Financial Officer | Jul 6, 2020 | Tax withholding | −31,873 | $2.20 | $70.12K | 77,586 |
| John L. Green Chief Financial Officer | Jul 6, 2020 | Option exercise | +109,459 | – | – | 109,459 |
| Dario Campana 10% owner | May 12, 2020 | Sale | −98,200 | $0.46 | $45.17K | 3,095,114 |
| Dario Campana 10% owner | May 11, 2020 | Sale | −22,281 | $0.46 | $10.25K | 3,271,033 |
| Dario Campana 10% owner | May 11, 2020 | Sale | −77,719 | $0.45 | $34.97K | 3,193,314 |
| Dario Campana 10% owner | May 8, 2020 | Sale | −100,000 | $0.46 | $46.00K | 3,293,314 |
| Dario Campana 10% owner | May 7, 2020 | Sale | −100,000 | $0.41 | $41.00K | 3,393,314 |
| Dario Campana 10% owner | May 6, 2020 | Sale | −1,800 | $0.40 | $720 | 3,493,314 |
| Dario Campana 10% owner | May 5, 2020 | Sale | −135,484 | $0.40 | $54.19K | 3,495,114 |
| Dario Campana 10% owner | May 4, 2020 | Sale | −4,795 | $0.40 | $1.92K | 3,630,598 |
| Dario Campana 10% owner | May 1, 2020 | Sale | −800 | $0.41 | $328 | 3,635,393 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Morris Arlene Director | Aug 27, 2026 | 45,510 | $1.67M | Aug 27, 2026 | Exercise of Stock Options |
| Healthcare Fund II L.P. Fairmount Director | Mar 31, 2026 | 7,000,000 | $242.62M | Mar 31, 2026 | Conversion of Series A Convertible Preferred Stock |
| Healthcare Fund II L.P. Fairmount Director | Jan 22, 2026 | 3,500,000 | $127.40M | Jan 22, 2026 | Purchased in public offering |
| D. Kearns Evan Officer | Dec 29, 2025 | 65,000 | $2.52M | Dec 26, 2025 | Performance Shares |
| Green John Officer | Dec 29, 2025 | 77,000 | $2.98M | Dec 26, 2025 | Performance Shares |
| Robinson John Officer | Dec 29, 2025 | 90,000 | $3.49M | Dec 26, 2025 | Performance Shares |
| Sachs Jessica Officer | Dec 29, 2025 | 82,642 | $3.20M | Dec 26, 2025 | Performance Shares |